September 25, 2024 03:28 PM EDT
Pharma
FDA+

EMA to dis­cuss Pfiz­er's sick­le cell drug Oxbry­ta af­ter pa­tient deaths

Nicole DeFeudis

Editor

The Eu­ro­pean Med­i­cines Agency will meet on Thurs­day to dis­cuss Oxbry­ta — the sick­le cell treat­ment Pfiz­er in­her­it­ed in its $5.4 bil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times